Research programme: autologous T-cell therapy - Iovance Biotherapeutics

Drug Profile

Research programme: autologous T-cell therapy - Iovance Biotherapeutics

Alternative Names: HPV TIL

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer Iovance Biotherapeutics; M. D. Anderson Cancer Center; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bladder cancer; Breast cancer; Human papillomavirus infections; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Sarcoma

Most Recent Events

  • 27 Jun 2017 Lion Biotechnologies is now called Iovance Biotherapeutics
  • 26 Apr 2017 Lion Biotechnologies enters into a manufacturing services agreement with PharmaCell to manufacture Lion's autologous cell therapy products
  • 19 Apr 2017 Preclinical trials in Sarcoma, Pancreatic cancer and Ovarian cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top